Logo image of M3V.DE

MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Stock Fundamental Analysis

FRA:M3V - Deutsche Boerse Ag - DE000A0LBFE4 - Common Stock - Currency: EUR

24.8  +0.4 (+1.64%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to M3V. M3V was compared to 11 industry peers in the Health Care Technology industry. M3V gets an excellent profitability rating and is at the same time showing great financial health properties. M3V has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

M3V had positive earnings in the past year.
In the past year M3V had a positive cash flow from operations.
In the past 5 years M3V has always been profitable.
M3V had a positive operating cash flow in each of the past 5 years.
M3V.DE Yearly Net Income VS EBIT VS OCF VS FCFM3V.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

M3V's Return On Assets of 17.22% is amongst the best of the industry. M3V outperforms 100.00% of its industry peers.
M3V has a better Return On Equity (25.58%) than 90.91% of its industry peers.
M3V has a better Return On Invested Capital (14.00%) than 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M3V is significantly above the industry average of 9.32%.
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROIC 14%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
M3V.DE Yearly ROA, ROE, ROICM3V.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

M3V's Profit Margin of 26.87% is amongst the best of the industry. M3V outperforms 100.00% of its industry peers.
In the last couple of years the Profit Margin of M3V has declined.
M3V's Operating Margin of 23.58% is amongst the best of the industry. M3V outperforms 100.00% of its industry peers.
M3V's Operating Margin has declined in the last couple of years.
M3V has a better Gross Margin (97.12%) than 81.82% of its industry peers.
In the last couple of years the Gross Margin of M3V has remained more or less at the same level.
Industry RankSector Rank
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
M3V.DE Yearly Profit, Operating, Gross MarginsM3V.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

M3V has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for M3V remains at a similar level compared to 1 year ago.
The number of shares outstanding for M3V remains at a similar level compared to 5 years ago.
There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
M3V.DE Yearly Shares OutstandingM3V.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
M3V.DE Yearly Total Debt VS Total AssetsM3V.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 4.66 indicates that M3V is not in any danger for bankruptcy at the moment.
The Altman-Z score of M3V (4.66) is better than 90.91% of its industry peers.
M3V has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.66
ROIC/WACC1.96
WACC7.16%
M3V.DE Yearly LT Debt VS Equity VS FCFM3V.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

M3V has a Current Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of M3V (1.52) is better than 63.64% of its industry peers.
A Quick Ratio of 1.52 indicates that M3V should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.52, M3V is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.52
M3V.DE Yearly Current Assets VS Current LiabilitesM3V.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

M3V shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
Measured over the past years, M3V shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.74% on average per year.
The Revenue has decreased by -2.14% in the past year.
The Revenue has been decreasing by -1.25% on average over the past years.
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
M3V.DE Yearly Revenue VS EstimatesM3V.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M3V.DE Yearly EPS VS EstimatesM3V.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 9.92, which indicates a very decent valuation of M3V.
Based on the Price/Earnings ratio, M3V is valued cheaper than 90.91% of the companies in the same industry.
M3V's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.54.
Industry RankSector Rank
PE 9.92
Fwd PE N/A
M3V.DE Price Earnings VS Forward Price EarningsM3V.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, M3V is valued a bit cheaper than 72.73% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, M3V is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.87
EV/EBITDA 9.34
M3V.DE Per share dataM3V.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

M3V has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.83%, M3V has a reasonable but not impressive dividend return.
M3V's Dividend Yield is a higher than the industry average which is at 3.63.
M3V's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 3.83%

5.2 History

On average, the dividend of M3V grows each year by 24.89%, which is quite nice.
Dividend Growth(5Y)24.89%
Div Incr Years0
Div Non Decr Years0
M3V.DE Yearly Dividends per shareM3V.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

M3V pays out 107.89% of its income as dividend. This is not a sustainable payout ratio.
The Dividend Rate of M3V has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP107.89%
EPS Next 2YN/A
EPS Next 3YN/A
M3V.DE Yearly Income VS Free CF VS DividendM3V.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
M3V.DE Dividend Payout.M3V.DE Dividend Payout, showing the Payout Ratio.M3V.DE Dividend Payout.PayoutRetained Earnings

More info and screens

MEVIS MEDICAL SOLUTIONS AG

FRA:M3V (7/15/2025, 7:00:00 PM)

24.8

+0.4 (+1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-27 2025-05-27
Earnings (Next)N/A N/A
Inst Owners20.44%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.14M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.83%
Yearly Dividend2.7
Dividend Growth(5Y)24.89%
DP107.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9.92
Fwd PE N/A
P/S 2.66
P/FCF 15.87
P/OCF 14.35
P/B 2.53
P/tB 2.53
EV/EBITDA 9.34
EPS(TTM)2.5
EY10.08%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.56
FCFY6.3%
OCF(TTM)1.73
OCFY6.97%
SpS9.32
BVpS9.79
TBVpS9.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROCE 19.88%
ROIC 14%
ROICexc 20.72%
ROICexgc 20.72%
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
FCFM 16.76%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
ROICexc(3y)27.89%
ROICexc(5y)26.51%
ROICexgc(3y)27.89%
ROICexgc(5y)26.51%
ROCE(3y)24.36%
ROCE(5y)24.64%
ROICexcg growth 3Y-4.16%
ROICexcg growth 5Y-6.12%
ROICexc growth 3Y-4.16%
ROICexc growth 5Y-6.1%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 227.51%
Cap/Sales 1.78%
Interest Coverage 250
Cash Conversion 76.1%
Profit Quality 62.38%
Current Ratio 1.52
Quick Ratio 1.52
Altman-Z 4.66
F-Score4
WACC7.16%
ROIC/WACC1.96
Cap/Depr(3y)151.22%
Cap/Depr(5y)111.1%
Cap/Sales(3y)0.98%
Cap/Sales(5y)0.77%
Profit Quality(3y)80.13%
Profit Quality(5y)97.8%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.41%
EBIT growth 3Y-3.25%
EBIT growth 5Y-10.94%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.74%
FCF growth 3Y-32.08%
FCF growth 5Y-14.82%
OCF growth 1Y-46.25%
OCF growth 3Y-29.89%
OCF growth 5Y-13.63%